An upgrade to the computer-aided detection product line from R2 Technology gives users a choice of operating points to set different sensitivity/false marker rates for microcalcifications and masses in the breast. The enhanced system allows users to set sensitivity to their own comfort levels, providing unprecedented flexibility, according to the company.
An upgrade to the computer-aided detection product line from R2 Technology gives users a choice of operating points to set different sensitivity/false marker rates for microcalcifications and masses in the breast. The enhanced system allows users to set sensitivity to their own comfort levels, providing unprecedented flexibility, according to the company.
The flexible operating points feature is part of R2's new software release, ImageChecker Version 8.1 Mammography CAD, which is displayed at the RSNA meeting. This version is being made available across the company's mammography CAD product line and to its entire installed base as an upgrade.
Version 8.1 includes two other major features. The new Malc Mark identifies regions of breast tissue that contain both a mass and calcifications. EmphaSize variable size CAD marks correlate the size of a CAD mark with the potential for malignancy: Small marks reflect a lower chance of malignancy, and large marks indicate more suspicious findings.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.